Endocan may predict the presence of coronary slow flow and coronary artery disease

Basit Öğe Kaydı
dc.authoridalpsoy, seref/0000-0003-3720-0076
dc.authoridAkyuz, Aydin/0000-0003-3304-4125
dc.authoridAydin, Cihan/0000-0002-1401-5727
dc.contributor.authorEfe, Muhammet Mucip
dc.contributor.authorAkyuz, Aydin
dc.contributor.authorAydin, Cihan
dc.contributor.authorDemirkiran, Aykut
dc.contributor.authorAlpsoy, Seref
dc.date.accessioned2024-10-29T17:58:56Z
dc.date.available2024-10-29T17:58:56Z
dc.date.issued2024
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractOBJECTIVE: Coronary artery disease (CAD) is frequent, but coronary slow flow (CSF) is a less common cardiovascular disease with a significant risk of mortality and morbidity. Endocan is a proinflammatory glycopeptide that has been investigated in cardiovascular diseases as well as some inflammatory diseases in recent years. We planned to compare the levels of endocan in both CAD and CSF in a similar population and examine the relationship of endocan with additional clinical variables. MATERIALS AND METHODS: In the trial, we included 169 consecutive subjects having a coronary angiography indication. According to the results of coronary angiography, 58 people were included in the CAD group, 52 were in the CSF group, and 59 people were in the control group. The control group includes those who did not have any lesions in their epicardial coronary arteries. Thrombolysis in myocardial infarction (TIMI)-frame counts (TFC) were calculated for all patients. RESULTS: Notably, 2.6% of the population in our study had CSF. Both the CAD (555 +/- 223 pg/mL) and CSF (559 +/- 234 pg/mL) groups had higher endocan levels than the control group (331 +/- 252 pg/mL) (p<0.001). There were similar endocan levels between the CAD and CSF groups. Endocan levels were shown to be favorably associated with mean TFC (r=0.267; p0.001). Serum endocan levels (particularly those above 450 pg/mL) and the presence of hyperlipidemia were the most important predictors of both CAD and CSF. CONCLUSION: Endocan levels are higher in CAD and CSF patients than in those with normal coronary arteries.
dc.identifier.doi10.1590/1806-9282.20240515
dc.identifier.issn0104-4230
dc.identifier.issn1806-9282
dc.identifier.issue8en_US
dc.identifier.pmid39230149
dc.identifier.scopus2-s2.0-85203224965
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1590/1806-9282.20240515
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14562
dc.identifier.volume70
dc.identifier.wosWOS:001307638300001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAssoc Medica Brasileira
dc.relation.ispartofRevista Da Associacao Medica Brasileira
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCoronary angiography
dc.subjectCoronary artery disease
dc.subjectCoronary vessels
dc.titleEndocan may predict the presence of coronary slow flow and coronary artery disease
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu